{
  "docId": "019de076-91e2-76fd-b3d2-f30dde172711",
  "docSlug": "0239a71f9c69421092604a0a694fdb09",
  "documentTitle": "AstraZeneca | Investor Conference Presentation Deck | 26 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 26,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "key_messages",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes specific drug names and market projections for 2028.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-91e2-76fd-b3d2-f30dde172711/9",
  "deckHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711",
  "deckJsonHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711.json",
  "deckAnchorHref": "/decks/019de076-91e2-76fd-b3d2-f30dde172711#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.53,
        "y": 0.38
      },
      "kind": "chart",
      "text": "Global IO market by 2028",
      "attrs": null,
      "subkind": "area",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "680f3af9-2413-4906-881f-019be5013460",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.15,
        "x": 0.53,
        "y": 0.65
      },
      "kind": "chart",
      "text": "Global ADC market by 2028",
      "attrs": null,
      "subkind": "area",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81cd979c-1a29-41a7-bc6d-0103daddd5e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "image",
      "text": "Lung, Breast, Haem, Gyn/GU, GI icons",
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0de6c1bb-e7be-4fbb-9e2c-2dbe953bcf8a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.04,
        "y": 0.72
      },
      "kind": "list",
      "text": "Cell therapy, Immune engagers, ADCs and RCs, DNA damage response, Tumour drivers and resistance, Epigenetics, Immuno-oncology",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "abbf7e52-57fb-4ca1-94ad-6cca56f79b54",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.05,
        "x": 0.53,
        "y": 0.65
      },
      "kind": "metric",
      "text": "$37bn",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ced95d3-1542-49c2-966d-0a141dcad611",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.05,
        "x": 0.53,
        "y": 0.38
      },
      "kind": "metric",
      "text": "$92bn",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7b8abff-5470-452b-a1e9-378794ba5db0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.03,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "1. GlobalData consensus dated March 2023 (Total Revenues 2023-2028). Collaboration partners: Compugen (rilvegestomig), LaNova Medicines (LM-305), KYM Biosciences (AZD0901).",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81f8b6de-d549-4922-b400-ad7875b3a6eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.7,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "title",
      "text": "Broadest pipeline unlocks novel combinations and strengthens tumour area leadership",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e23bc53e-75ad-40cd-b8f2-dcb4d8585c1d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "Oncology – driving towards oncology leadership by 2030",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e644fc74-0fb5-49a4-b43d-8e14baf3b710",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 7,
      "beatId": "aadac6c5-85ff-4c00-8a67-6ccfa3236c41",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Rising Success",
      "beatSlug": "rags-to-riches-rising-success",
      "evidence": "The deck showcases AstraZeneca's successes in various disease areas, including oncology and rare disease.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 9,
      "from": 4,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "4e7501eb-74e6-4ae7-8a18-04c13b6f5ddc",
      "evidence": "The deck outlines AstraZeneca's growth strategy and supporting data.",
      "position": 0,
      "objective": "How AstraZeneca's growth strategy will drive growth through 2030",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}